Search
Pyrimethamine
go.drugbank.com/drugs/DB00205ApprovedInvestigationalVet approvedOne of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Mixtures: SULFADOXINA 500 MG + PIRIMETAMINA 25 MG TABLETASProducts: DARAPRIM 25 MG TABLETASTea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalIt has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438]. … It may be referred to as _Melaleuca alternifolia_ oil.
Synonyms: Snow-in-summer leaf oilMixtures: Wet WipesStannous fluoride
go.drugbank.com/drugs/DB11092ApprovedInvestigationalIt is an FDA-approved over-the-counter product. … Although similar in function and activity to Sodium Fluoride (NaF), the conventionally added ingredient in toothpastes, stannous fluoride has been shown to be more effective at stopping and reversing dental
Categories: Compounds used in a research, industrial, or household settingProducts: H E B Restore and Defend, Pro-Den RxTuroctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalIt was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. … During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p454) … Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties.
Isradipine
go.drugbank.com/drugs/DB00270ApprovedIt exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells … It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class.
Products: VASCAL UNO 5MG, DYNACIRC SRO 5 MGClofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawn[A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis … It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.
Products: CLOFZIMIN® 100 MG, Fazim 50 mg CapsuleCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Products: Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 7 ADETHistrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41710] GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]
Synonyms: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamideLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA.